Alliancebernstein L.P. Decreases Stock Holdings in Boston Scientific Corporation $BSX

Alliancebernstein L.P. reduced its position in Boston Scientific Corporation (NYSE:BSX) by 9.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,986,478 shares of the medical equipment provider’s stock after selling 302,058 shares during the period. Alliancebernstein L.P. owned 0.20% of Boston Scientific worth $291,570,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BSX. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter worth approximately $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific during the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth $26,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several research analyst reports. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Wells Fargo & Company decreased their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Mizuho dropped their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.00.

Boston Scientific Trading Up 0.9%

Shares of Boston Scientific stock opened at $69.15 on Monday. The company has a market cap of $102.61 billion, a P/E ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a 50-day simple moving average of $82.47 and a two-hundred day simple moving average of $93.21.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the business posted $0.70 earnings per share. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.